arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

MiNK Therapeutics, Inc.

INKT

$10.90 ▼ -0.84 (-7.16%) at close

7 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Bullish

auto_awesome

Analytical Summary

MiNK Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $46.5M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC 70.2% ↗

FCF / Share $-1.39 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-12.49M

↓ -15.9% —

FCF / Share Free cash flow per share

$-1.39

↑ +45.2% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns ↑

Financial Health ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	-2.4% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	56.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	21.2% Good Good Year-over-year change in earnings per share Optimal: > 10%	28.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-15.9% Weak ↓ Weak Declining Year-over-year change in net income	52.0% Excellent ↑ Excellent Improving Year-over-year change in net income	19.8% Good ↑ Good Improving Year-over-year change in net income	7.4% Fair Fair Year-over-year change in net income	-86.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	45.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	45.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	18.8% Good Good Year-over-year change in free cash flow	-13.0% Weak Weak Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	0.47x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.43x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.52x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	70.2% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	45.5% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	100.3% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	6092.6% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-94.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	21.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-88.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-197.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-503.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-144.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-70.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-321.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	87.8% Excellent → Excellent Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+485%)	55.1% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+267%)	124.4% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+729%)	—	-127.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-947%)	30.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+101%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	-114.93x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-121.38x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-818.61x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-2860.38x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-11.66x Weak Weak Operating income divided by interest expense Optimal: > 5x	-6.00x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-13.36M	$-4.58M	$-3.37M	$-19.64M	$-38.89M	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-2.93	$-2.86	$-6.54	$-8.30	$-11.60	—	—
Free Cash Flow per Share (USD)	$-1.39	$-2.53	$-4.61	$-5.68	$-5.02	—	—
Book Value per Share (USD)	$-3.33	$-4.94	$-5.22	$-0.12	$7.10	—	—
Tangible Book Value per Share (USD)	$-3.33	$-4.94	$-5.22	$-0.12	$7.10	—	—
Basic Weighted Avg Shares (shares)	4.27M	3.77M	3.44M	3.37M	2.60M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$816.52K	$-1.97M	$-7.80M	$7.72M	$23.17M	$-10.13M	—
Total Equity (USD)	$-14.23M	$-19.59M	$-18.06M	$-401.30K	$23.78M	$-53.87M	$-36.33M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$181.75K	$215.44K	$204.62K	$121.75K	$77.96K	$55.06K	—
Net Income, GAAP (USD)	$-12.49M	$-10.78M	$-22.46M	$-27.99M	$-30.21M	$-16.24M	—
Operating Cash Flow (USD)	$-5.93M	$-9.56M	$-15.76M	$-18.87M	$-12.83M	$-8.34M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

MiNK Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare INKT with peers